

Market Announcement

3 November 2023

Cleo Diagnostics Ltd (ASX: COV) – Trading Halt

Description

The securities of Cleo Diagnostics Ltd ('COV') will be placed in trading halt at the request of COV, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Tuesday, 7 November 2023 or when the announcement is released to the market.

Issued by

Sam Dorland

Adviser, Listings Compliance

Request for Trading Halt

3 November 2023

Melissa Nedelkovska
Adviser, Listings Compliance
ASX Compliance – Perth
Listing Compliance - Perth

Dear Ms Nedelkovska

Pursuant to ASX Listing Rule 17.1, Cleo Diagnostics Ltd (the Company) (ASX: COV) requests that the ASX grants a trading halt with respect to the Company's shares.

The trading halt is requested pending an announcement to be made by the Company to the market in connection with the publication reporting results of Cleo's first clinical validation study for the triage test ("purpose").

In accordance with Listing Rule 17.1, the Company provides the following information in relation to the request:

1. The trading halt is necessary to assist the Company in managing its continuous disclosure obligations as the Company expects to make a material announcement to the market for the stated purpose.
2. The Company requests that the trading halt remains in place until the earlier of commencement of normal trading on Monday 6 November 2023, or when the announcement regarding the purpose is released to the market.
3. The Company expects to make the announcement to the market before the commencement of normal trading on Monday 6 November 2023.
4. The Company is not aware of any reason why the trading halt should not be granted or of any further information necessary to inform the market about the trading halt.

Please contact me if you require any further information concerning this matter.

Released with the authority of the Board.



Ms Pauline Moffatt
Company Secretary

Cleo Diagnostics Ltd ASX:COV

Level 2, 480 Collins Street, Melbourne, VIC, 3000
ACN 655 717 169 T +61 3 9614 0600 E office@cleodx.com

Directors
Chair and Non-Executive Director: **Adrien Wing**
Chief Executive Officer and Executive Director: **Dr Richard Allman**
Chief Scientific Officer and Executive Director: **Dr Andrew Stephens**
Non-Executive Director and Lead Medical Advisor: **Professor Tom Jobling**
Non-Executive Director: **Lucinda Nolan**

cleodx.com